| Published time |
Research type |
Research object |
Follow-up time |
Treatment |
Outcome |
| 2009 [4] |
Prospective cohort study |
207 patients with IgAN |
6 years |
High-dose losartan (200 mg/d), normal- dose (100 mg/d), normal–dose enalapril (20 mg/d) and low-dose (10 mg/d) |
Patients on high-dose ARB had significantly higher eGFR (p<0.0005) and lower proteinuria (p<0.005) |
| 2011 [5] |
Retrospective cohort study |
66 IgAN patients with an eGFR＜60ml/min |
2-17 years |
ACEI group (n=20), ARB group (n=23), Control group (n=23, treated with antiplatelet agents) |
Renal survival rate was significantly higher in the ACEI or ARB groups than in the control group |
| 2012 [8] |
Retrospective cohort study |
63 IgAN patients with an eGFR of ＜60 ml/min and proteinuria ≥ 0.5 g/d |
2-24 years |
RASI alone group (n=33); Combination group (n=30 treated with steroids and RASIs) |
Renal function, the amount of proteinuria, and histological backgrounds were not significantly different |
| 2012 [7] |
Meta-analysis |
6 RCTs of combination therapy with ACEI plus ARB (109 patients) |
Not known |
Combined treatment with ACEI plus ARB VS treatment with ACEI/ARB alone |
Combined treatment was more effective than ACEI/ARB alone for reducing daily proteinuria |
| 2013 [6] |
Prospective cohort study |
60 patients with IgAN, proteinuria < 0.5 g/d, normal blood pressure and renal function |
5 years |
Ramipril 2.5 mg daily or no treatment |
Ramipril group does not offer any benefit by evaluating proteinuria, eGFR and hypertension |
